Experts
    • Infectious Disease
    • Internal Medicine
    • HIV
    • Molecular Epidemiology
    Director, HIV Prevention Research, Beth Israel Deaconess Hospital
    Director, HIV Prevention Research, Beth Israel Deaconess Hospital
    Kenneth Mayer’s clinical research career has focused on the natural history and transmission of HIV in the US and in Asia, having developed some of the very first cohort studies and prevention interventions dealing with the AIDS epidemic. Dr. Mayer published some of the earliest data describing the prevalence of HIV among men who had sex with men in the early 1980’s, and co-authored the first paper showing that antiretroviral drugs suppressed HIV replication in semen and the first safety study of tenofovir vaginal gel in humans. Dr. Mayer was trained in Internal Medicine at Beth Israel Hospital (1977-80) and in Infectious Diseases and Molecular Epidemiology at Brigham and Women’s Hospital (1980-83). As the founding Medical Research Director of Fenway Health, he created a community health research program that has developed an international reputation for its capability to conduct community-based peer reviewed research. He is currently a Professor at Harvard Medical School, a Professor in Global Health and Population at the Harvard TC Chan School of Public Health, and Attending Physician and Director of HIV Prevention Research at Beth Israel Deaconess Hospital in Boston. Starting in 1994, he has been a Principal Investigator of NIH-funded HTVN, HPTN, and MTN clinical trials units, focusing on bio-behavioral HIV prevention research. He has co-authored more than 600 peer-reviewed publications, co-authored the first text on AIDS for the general public and has co-edited 5 academic texts. He has served on the national boards of amfAR, HIVMA, and GLMA, was a member of the CDC/HRSA HIV/AIDS Advisory Committee, and is currently a member of the Governing Council of the International AIDS Society, and serves on the PEPFAR Scientific Advisory Board and the PCORI Health Disparities Advisory Board.
    • Infectious Disease
    • Internal Medicine
    • HIV
    Assistant Professor of Medicine, Division of Infectious Diseases, Emory University School of Medicine
    Assistant Professor of Medicine, Division of Infectious Diseases, Emory University School of Medicine
    Dr. Colleen F. Kelley is Assistant Professor of Medicine in the Division of Infectious Diseases and Assistant Professor of Epidemiology at the Rollins School of Public Health at Emory University in Atlanta, Georgia. She is Associate Director for Clinical/Translational Research for the Emory Center for AIDS Research (CFAR) Clinical Core. The current focus of Dr. Kelley's research is on translational immunology studies of HIV susceptibility in men who have sex with men (MSM) with a particular interest in biomedical prevention interventions. She is currently principal investigator of two ongoing studies examining rectal mucosal immunology in men who have sex with men (MSM); one which focuses on the rectal mucosal effects of condomless receptive anal intercourse and one to understand the potential interaction of Pre-exposure Prophylaxis (PrEP) and rectal lubricant use in the rectal mucosa. Dr. Kelley is also a faculty member in the PRISM Health group in the Rollins School of Public Heath that conducts various large research studies focused on HIV prevention in MSM. They recently concluded the InvolveMENt study where more than 560 white and black MSM in Atlanta were followed for incident HIV and sexually transmitted infections (STI) in order to examine factors associated with racial disparities in HIV and STI. They have now begun to enroll a new cohort of young, black MSM who are at-risk of HIV infection designed to delineate relationships between substance use and HIV risk behavior. Within this cohort, Dr. Kelley has embedded an optional PrEP program as ‘standard of care’ for HIV prevention and will examine PrEP uptake and adherence in this key population. She has also consulted with the Fulton County Health Department to establish a PrEP clinic to ensure access to PrEP for underserved populations in Atlanta. Dr. Kelley is a graduate of the Emory University School of Medicine (MD) and the Rollins School of Public Health (MPH). Dr. Kelley completed her Internal Medicine training at the University of California San Francisco and Infectious Diseases fellowship at Emory University. She practices outpatient HIV medicine at the Grady Infectious Disease Program and attends on the Infectious Diseases consultation service and inpatient HIV service at Grady Memorial Hospital
    • Infectious Disease
    • Internal Medicine
    • HIV
    • HIV and STI prevention
    • Medical Director of Prevention Programs at Montefiore AIDS Center
    Sachin Jain, MD MPH is a board-certified Infectious Diseases & HIV specialist and Medical Director of HIV Prevention Programs at the Montefiore AIDS Center, where he is leading efforts to rapidly roll out PEP & PrEP in the Bronx for high-risk individuals. He completed his medical degree at Rush Medical College and MPH at the Johns Hopkins Bloomberg School of Public Health. As an Internal Medicine resident at Yale-New Haven Hospital, he co-founded an adult refugee clinic and subsequently co-authored a book chapter on the management of HIV and other sexually transmitted infections in refugee patients. He went on to complete an Infectious Diseases fellowship at BIDMC/Harvard and research training at The Fenway Institute, where he was involved with clinical aspects of HPTN, MTN, HVTN, and other HIV prevention studies. His research on biobehavioral aspects of HIV post-exposure prophylaxis (PEP) and pre-exposure prophylaxis (PrEP) has been published in several high-impact Infectious Diseases and HIV/AIDS journals. He serves as an active member of the STI subcommittee of the New York State AIDS Institute's HIV Quality of Care Committee, the New York State AIDS Advisory Council “Ending The Epidemic” Subcommittee, and the New York State AIDS Institute’s STI guidelines committee.
    • Internal Medicine
    • Public Health
    • HIV
    • Deputy Director, Science at Amsterdam Institute for Global Health and Development
    Catherine Hankins is an Honorary Professor at the London School of Hygiene and Tropical Medicine in the Faculty of Epidemiology and Population Health. She is also Professeure associée at the Université de Montréal in the Département de médicine sociale et préventive. She is Deputy Director, Science at the Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, Academic Medical Centre, University of Amsterdam. She leads AIGHD’s HIV prevention research group and knowledge translation/communication strategy, represents AIGHD in the Learning and Analysis Unit of the Health Insurance Fund, teaches/supervises students, and is involved in a number of funded projects. She is Chair of the Scientific Advisory Group of the US National Institutes of Health HIV Prevention Trials Network since 2013 and Chair of the Scientific Advisory Board of the AIDS Programme of Research in South Africa (CAPRISA) at the University of KwaZulu-Natal, Durban since 2012. She is a board member of the AIDS East-West Foundation based in Amsterdam; the Swiss Vaccine Research Institute in Lausanne; and the development NGO HealthBridge in Ottawa (emeritus). Dr Hankins is a trustee of the UK HIV Research Trust since 2013 and a member of the International AIDS Society Industry Liaison Forum since 2010. She was named to the Order of Canada in January 2015. A Fellow of the Royal College of Physicians, Canada in community medicine, she was the Chief Scientific Adviser to UNAIDS and Associate Director from 2002 for almost a decade. She headed up its scientific knowledge translation team focused on HIV prevention trials – ensuring the ethical and participatory conduct of trials, communicating about results, convening mathematical modelling teams, and supporting country implementation of proven biomedical HIV prevention modalities. She led UNAIDS’ work on women in clinical trials and was the editor of the popular UNAIDS’ science blog HIV This Week. She spearheaded UNAIDS work on prevention trial ethics, updating the UNAIDS/WHO Ethical Considerations in Biomedical HIV Prevention Trials, and creating the Good Participatory Practice in Biomedical HIV Prevention Trials with AVAC. Dr. Hankins is a reviewer for a number of scientific journals and has authored or co-authored over 200 peer-reviewed publications.
    • Infectious Disease
    • Internal Medicine
    • HIV
    Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA)
    Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA)
    • Pro Vice-Chancellor (Research) at University of KwaZulu-Natal
    Salim S. Abdool Karim, MBChB, PhD is a South African clinical infectious diseases epidemiologist who is widely recognised for his research contributions in HIV prevention and treatment. He is Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA) and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal, South Africa. He is also Professor of Clinical Epidemiology at Columbia University and Adjunct Professor of Medicine at Cornell University. He previously served as President of the South African Medical Research Council. His clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. He was co-leader of the CAPRISA 004 tenofovir gel trial that provided proof-of-concept that antiretroviral drugs prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents which have been used in several HIV vaccine candidates. Dr Abdool Karim is Chair of the UNAIDS Scientific Expert Panel and serves on the Gates Foundation’s Global Health Scientific Advisory Board, the UNAIDS-Lancet Commission as well as the WHO Expert Panel on sexually transmitted infections and HIV. He is a member of the Academy of Science of South Africa, Royal Society of South Africa, African Academy of Sciences and The World Academy of Sciences. He is a Foreign Associate of the US National Academy of Medicine (formerly Institute of Medicine) and a member of the American Academy of Microbiology. He is a member of the Editorial Board of the New England Journal of Medicine.
    • Internal Medicine
    • Epidemiology
    • HIV
    Medical Research Council Clinical Trials Unit at UCL, and 56 Dean Street Sexual Health Clinic, London UK
    Medical Research Council Clinical Trials Unit at UCL, and 56 Dean Street Sexual Health Clinic, London UK
    • Professor of Clinical Epidemiology at Imperial College
    Sheena McCormack, MBBS, MSc, FRCP, Dip Ven, is a Clinical Epidemiologist who has been coordinating HIV prevention trials since 1994, when she joined what subsequently became the Medical Research Council Clinical Trials Unit. From the outset she has worked on HIV vaccine trials, all Phase I/II, in Europe and Africa. Since 1998 she has been involved in microbicide trials and was Chief Investigator of a Phase III vaginal microbicide trial that enrolled 9,385 women through six research centres in Southern Africa. Sheena has been a Consultant in HIV/GU Medicine since 1991, initially at the Royal Devon and Exeter Hospitals and since 1996 at Chelsea & Westminster Hospital working at the Dean Street clinic in Soho. She recently reported the PROUD PrEP study conducted in gay and other men who have sex with men which showed a very high level of effectiveness for daily oral Truvada in the real world setting of 13 sexual health clinics in England. PROUD was the first HIV prevention trial to use a randomization to immediate or deferred access in order to compare PrEP to no-PrEP. The no-PrEP control group was necessary to assess the impact on risk behaviours and determine whether any change in these could undermine biological efficacy. Although her primary current focus is to ensure that PrEP becomes available to those who need it in the UK and Europe, she continues to work on HIV vaccine trials and maintains a keen interest in microbicides. Sheena became a Professor of Clinical Epidemiology at Imperial College in August 2012, and joined UCL in August 2013 when the MRC Clinical Trials Unit became part of UCL.
    • Infectious Disease
    • Internal Medicine
    • HIV
    Vice Chair and Professor, Dept of Global Health, University of Washington
    Vice Chair and Professor, Dept of Global Health, University of Washington
    • Professor of Medicine and Epidemiology at University of Washington
    Dr. Baeten is Vice Chair and Professor in the Department of Global Health at the University of Washington, where he is also Professor of Medicine and Epidemiology. His research focuses on the prevention of HIV-1 and other sexually transmitted diseases, including clinical trials of novel prevention interventions, epidemiologic studies of risk factors for HIV-1 transmission, and biobehavioral and implementation science research aimed at optimizing prevention delivery. He co-chaired the Partners PrEP Study, a randomized clinical trial that provided definitive evidence that pre-exposure prophylaxis (PrEP) protected against HIV-1 acquisition. Current projects include a) a multinational phase III trial of dapivirine vaginal ring for HIV-1 prevention in women (MTN-020/ASPIRE, through the NIH Microbicides Trials Network, for which he serves as protocol chair), b) implementation science work to deliver antiretroviral treatment and PrEP for HIV-1 prevention (the Partners Demonstration Project), c) studies exploring use of hormonal contraception as a risk factor for HIV-1 (the ECHO Study), and d) collaborative studies of immunologic and virologic factors that influence HIV-1 transmission.
    • HIV
    President, Australian Federation of AIDS Organisations
    President, Australian Federation of AIDS Organisations
    • Research Fellow at Kirby Institute for Infection and Immunity in Society
    Dr Bridget Haire is a research fellow at the Kirby Institute for Infection and Immunity in Society at UNSW Australia, and the President of the Australian Federation of AIDS Organisations (AFAO), the federation for the community-based response to HIV in Australia. She has published in the areas of research ethics, public health and human rights, particularly with regard to HIV and other blood-borne infections, sexual health and Ebola. Her academic work has included lecturing in public health ethics, global health, medical ethics, bioethics, and medical humanities at the Universities of NSW and Sydney. She has a research affiliation with the Centre for Values, Ethics and the Law in Medicine at the University of Sydney. Bridget has a strong commitment to community-based responses and before moving to full time research, she worked in HIV and sexual and reproductive health for more than 20 years as a journalist, editor, policy analyst and advocate. She is a consultant for the Australia-China Human Rights Technical Co-operation Program on sexual and reproductive health rights for the Australian Human Rights Commission, and serves on the Global Emerging Pathogens consortium and the New South Wales Assessment Panel for the Management of People with HIV Who Risk Infecting Others. She was the medical ethicist on the Data Safety Monitoring Board for the South African HIV prevention study CAPRISA 008. She has a Masters of Bioethics (hons) and a Doctorate on standards of care in HIV prevention research.
    • Infectious Disease
    • Internal Medicine
    • HIV
    Associate Director of the UCLA Center for Clinical AIDS Research & Education
    Associate Director of the UCLA Center for Clinical AIDS Research & Education
    • Associate Professor of Medicine at The University of California, Los Angeles
    Raphael Landovitz’s clinical research career focuses on optimizing the use of HIV antiretroviral therapy for both HIV treatment and HIV prevention. Dr. Landovitz was trained at Princeton University and Harvard Medical School. He completed post-graduate training in internal medicine at Brigham and Women’s Hospital (1996-1999) and Infectious Diseases and HIV Medicine at Brigham and Women’s Hospital and Massachusetts General Hospital (1999-2001). The served as Chief Medical Resident at the Brigham and Women’s Hospital from 2001-2002. He served on the faculty of the Divison of Infectious Diseases at the Brigham and Women’s Hospital from 2001-2005, and then as Medical Co-Director of the Vietnam CDC-Harvard Medical School AIDS Partnership. Dr. Landovitz relocated to Los Angeles in 2006, and is Currently Associate Professor of Medicine in the Division of Infectious Diseases at UCLA. He is Associate Director of the UCLA Center for Clinical AIDS Research & Education. Funded by the NIH, California HIV Research Program (CHRP), The County and City of Los Angeles, he has led combination prevention intervention studies and projects using Post-exposure (PEP) and Pre-exposure (PrEP) strategies for Men who have sex with men, transgender women, and cis-gender women. He works in the DAIDS-funded AIDS Clinical Trials Group (ACTG), HIV Prevention Trials Network (HPTN) and the NICHD-funded Adolescent Trials Network (ATN), and serves as the Clinical Research Site leader of the UCLA CARE Center Clinical Research Site for the DAIDS-funded networks. He is the principal investigator of a multisite PrEP demonstration project in Los Angeles County, and the protocol chair of a Phase 2a and upcoming Phase 2b/3 studies of long-acting injectable PrEP using GSK1265744 (cabotegravir). Dr. Landovitz is the co-director of the Combination HIV Prevention Core of the UCLA Center for HIV Identifcation, Prevention, and Treatment Services (CHIPTS), and co-director of the Biomedical HIV Prevention Strategies subcommittee of the UCLA AIDS Institute. He was awarded the John Carey Young Investigator Award by the ACTG in 2010.
    Charlene S. Dezzutti, Ph.D., is an associate professor in the department of obstetrics, gynecology and reproductive sciences, division of reproductive infectious diseases and immunology, at the University of Pittsburgh School of Medicine and a member at the University of Pittsburgh-affiliated Magee-Womens Research Institute. In addition, she holds a secondary appointment in the department of infectious diseases and microbiology at the University of Pittsburgh Graduate School of Public Health. A cell biologist specializing in viral immunology, Dr. Dezzutti is the principal investigator of the Laboratory Center at the Microbicide Trials Network (MTN), an HIV/AIDS clinical trials network established by in 2006 by the U.S. National Institutes of Health (NIH). In this capacity, Dr. Dezzutti is responsible for overseeing the collection, testing and reporting of results from biologic samples; assisting in the development and quality assurance of local laboratory capacity at study sites; and identifying and implementing state-of-the-art assays and technologies to advance the scientific agenda of the MTN. Dr. Dezzutti joined the University of Pittsburgh faculty in 2005 after 13 years at the U.S. Centers for Disease Control and Prevention (CDC), where she was a senior research microbiologist in the Laboratory Branch of the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention. While at the CDC, Dr. Dezzutti developed the cervical and colorectal explant models that serve as a method for evaluating the anti-HIV activity and tissue toxicity of microbicides in cell culture. Another area of Dr. Dezzutti’s research uses an assay that exposes mucosal tissue from people who used microbicide products to HIV in the laboratory. This assay helps to determine whether microbicide products are effective in protecting the tissue from HIV infection, streamlining product selection to move only the safest and most promising microbicides to testing people. She has co-authored over 80 peer-reviewed publications and 14 reviews.
    • Infectious Disease
    • Internal Medicine
    • HIV
    HIV and Infectious Diseases consultant at the Toronto General Hospital
    HIV and Infectious Diseases consultant at the Toronto General Hospital
    • Assistant Professor, Dept of Medicine at University of Toronto
    Dr. Bogoch is an Assistant Professor at the University of Toronto in the Department of Medicine, and is an Infectious Diseases consultant at the Toronto General Hospital. He completed medical school and Internal Medicine residency training at the University of Toronto, and then specialized in Infectious Diseases at the Harvard Partners program. He holds a Masters Degree in Clinical Epidemiology from the Harvard School of Public Health, and completed an HIV fellowship at the Massachusetts General Hospital. Dr. Bogoch’s clinical and research interests focus on HIV prevention strategies. He created a dedicated HIV Prevention Clinic at the Toronto General Hospital to improve the quality of care provided to individuals seeking care for HIV Pre Exposure Prophylaxis (PrEP) and Post Exposure Prophylaxis (PEP). This clinic serves as a major hub for HIV prevention research. His recent work evaluates the transition of individuals at high risk of HIV acquisition from PEP to PrEP care. Dr. Bogoch is also involved in numerous community outreach programs promoting HIV prevention.
    • Internal Medicine
    • Public Health
    • HIV
    • AIDS
    Board of Directors, San Francisco AIDS Foundation
    Board of Directors, San Francisco AIDS Foundation
    • Faculty at UCSF
    Lisa Sterman began her career in HIV as a volunteer on the inpatient AIDS ward, 5A, at San Francisco General Hospital in 1987. She received her BA from University of California, Berkeley in 1987, and Masters in Public Health in epidemiology and biostatistics from University of California, Berkeley in 1990. She worked to help set up the first HIV data base at the Veteran’s Administration in San Francisco from 1988-1990. In 1994 she received her MD from Emory University. She worked on many HIV projects for the Centers for Disease Control as well as Emory University School of Public Health while in Medical school. She returned back to northern California to complete her residency in Internal Medicine at the University of California, San Francisco, School of Medicine, in 1997. She has worked in private practice and has been a principal and Sub-Principal Investigator on many phase 2-4 clinical trials for HIV for 18 years, and has authored and co-authored many articles in the professional and lay press on HIV topics. She is on faculty at the University of California, San Francisco, as well as California Pacific Medical Center teaching HIV clinical care to students and residents. Dr. Sterman also serves on the Board of Directors for the San Francisco AIDS Foundation whose goal is to be the first US City to end HIV-related deaths, transmission and stigma in its nationally recognized “Getting to Zero” Campaign.
    • Critical Care Medicine
    • Internal Medicine
    • Pulmonary Disease
    • HIV
    • Professor of Medicine at UCSF
    Robert Grant has 31 years of experience with HIV/AIDS research and clinical care. His work has focused on HIV epidemiology, viral fitness, drug resistance, and the impact of antiretrovirals on transmission, including early therapy, and post- and pre-exposure prophylaxis. He led trials of PrEP including iPrEx and HPTN 067 ADAPT. The HPTN 067/ADAPT trials randomized men and women to receive daily or non-daily PrEP using open-label oral FTC/TDF. Dr Grant is the Betty Jean and Hiro Ogawa Investigator at the Gladstone Institutes, Professor of Medicine at UCSF, Chief Medical Officer at the San Francisco AIDS Foundation, and a Consultant with the World Health Organization. He trained at University of California, San Francisco for medical school, residency in internal medicine, and fellowships in Pulmonary and Critical Care Medicine and Molecular Medicine at UCSF. His clinical work includes leading the UCSF Sexual Health Improvement Project and oversight of PrEP services for the San Francisco AIDS Foundation, which hosts one of the largest sexual health practices in San Francisco. Dr. Grant has served as an advisor to the FDA, CDC, and WHO, and is a member of the American Society of Clinical Investigation and the American Association of Physicians.
    • Infectious Disease
    • HIV
    • HSV
    • HCV
    I am a Staff Scientist in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases, physically based on the medical campus of Johns Hopkins University. I hold academic appointments at Johns Hopkins University as an Assistant Professor of Medicine in the Division of Infectious Diseases in the Department of Medicine and an Assistant Professor of Epidemiology at the Bloomberg School of Public Health in an unpaid part time capacity. I am also part of the HIV Trials Network Laboratory Center. I am a laboratory scientist and infectious disease epidemiologist engaged in studies of HIV, HCV and HSV-2 both domestically and internationally. I hold a PhD in epidemiology, a MS in biotechnology and an MBA all from Johns Hopkins University. My primary areas of interest include the development of methods for estimating incidence from cross-sectional surveys, the impact of HIV subtype on disease progression, and the development of serologic and molecular tools to investigate questions related to infectious disease epidemiology. I have worked in infectious disease laboratories since 1990 and have coauthored more than 130 peer reviewed publications.
    • Pediatrics
    • HIV
    Deputy Director, Research & Partnership Advancement Unit, College of Health Sciences, Obafemi Awolowo University
    Deputy Director, Research & Partnership Advancement Unit, College of Health Sciences, Obafemi Awolowo University
    • Associate Professor of Paediatric Dentistry at Obafemi Awolowo University
    Dr Morenike Ukpong is an Associate Professor of Paediatric Dentistry at the Obafemi Awolowo University, Ile-Ife, Nigeria and a Consultant with institution’s teaching hospital. She holds a Fellowship of the West African College of Surgeon, a Masters degree in Business Administration and a Bachelor’s degree in Dentistry. She serves as the Deputy Director of the Research and Partnership Advancement Unit of the College of Health Sciences, Heads the Research and Innovation Support Unit of the College and coordinates the Health Professions Training Unit of the Institute of Public Health, Obafemi Awolowo University which sources for, designs and nurtures local, regional and international capacity building programmes for health care providers. Her research, programme, advocacy and policy related endeavors over the last two decades had covered the field of oral health of children and adolescents, HIV and AIDS especially with respect to promoting the rights of people living with HIV and key populations. She has also done extensive work on the sexual and reproductive health and rights of adolescents. She has worked with multiple national, regional and international Institutions and served as members of various committees working to promote research, develop and revise policies, and develop and implement programmes. She has 119 peer review articles to her credit and has made 130 abstract presentations at various national, regional and international conferences as at November, 2015.
    • Infectious Disease
    • Public Health and General Preventive Medicine
    • HIV and STI prevention
    • HIV epidemiology
    • Mathematical modelling
    Research Fellow at Imperial College London
    Research Fellow at Imperial College London
    • Research Fellow at Imperial College
    Dr Kate Mitchell is a Research Fellow in the Department of Infectious Disease Epidemiology at Imperial College, London. Her research has focussed upon using mathematical modelling to understand the population dynamics of human infectious diseases, including HIV and other STIs, and to identify optimal control strategies. She currently works for the HIV Prevention Trials Network (HPTN) Modelling Centre, which is based at Imperial College, providing modelling support for clinical trials at every stage from development to post-trial analysis. She has particular expertise in modelling HIV and STI transmission and control among key populations in concentrated epidemics, including men who have sex with men in India and the US, female sex workers in India and China, and serodiscordant couples in Nigeria. She has studied a variety of prevention interventions, including PrEP, treatment as prevention, condom promotion and increased testing rates. Dr Mitchell holds a BSc in Biological Science from the University of Edinburgh and an MSc in Epidemiology from Imperial College London. She undertook her PhD modelling immunity to urogenital schistosomiasis at the University of Edinburgh, before moving into HIV epidemiology.
  • Dr. Jessica Haberer received her medical degree from Yale University, as well as a master's degree in Health Services Research from Stanford University. She completed an internship and residency in Internal Medicine at the University of California, San Francisco. After finishing her training, Dr.Haberer worked for the William J. Clinton Foundation HIV/AIDS Initiative in Beijing, China, where she served as a Clinical and Research Advisor to the Chinese National Center for AIDS. Upon returning to the United States, she joined the Department of Medicine at the University of California, San Francisco as a Clinical Educator. Dr. Haberer developed in interest in adherence to HIV antiretroviral therapy (ART) while in China and began studying multiple measures of ART adherence among children and adults in developing settings. She joined the Massachusetts General Hospital Center for Global Health and Harvard Medical School Department of Medicine in 2008, where she is actively involved in the study of real-time adherence monitoring and intervention strategies for ART and pre-exposure prophylaxis against HIV infection. Her current projects are based in Uganda, Kenya, and South Africa.
    • Infectious Disease
    Valdilea G. Veloso is an Infectious Diseases and HIV Specialist. She serves as Associate Director of the STD&AIDS Laboratory and Co-PI of the HIV/AIDS Treatment and Prevention Clinical Trials Unit at the Evandro Chagas National Institute of Infectious Diseases (INI) /Oswaldo Cruz Foundation in Rio de Janeiro, Brazil, where she is also a faculty member of the Master & PhD Program on Clinical Research in Infectious Diseases. She is a Senior Researcher at INI/Fiocruz and her clinical and research interests focus on HIV prevention strategies for MSM and Trangender women, HIV Acute infection and Tuberculosis. Dr Veloso works in the NIAID/NIH- funded HIV Prevention Trials Network (HPTN) and AIDS Clinical Trials Group(ACTG) at Fiocruz. She is currently deeply involved in implementation science work to deliver PrEP for HIV prevention for MSM and TGW in several states in Brazil (the PrEP Brazil Project). She is a member of the Brazilian Antiretroviral Guidelines Committee, the Pre Exposure Prophylaxis Advisory Committee for the Brazilian Ministry of Health and the Scientific and Technical Treatment Advisory Committee of the UNAIDS. Dr Veloso received her MD from Rio de Janeiro State University. She holds a Masters Degree in Infectious diseases from the Federal University of Rio de Janeiro and a PhD Degree from the Sergio Arouca National School of Public Health. She joined Fiocruz in 1988, after finishing her training in Infectious Diseases at the Emilio Ribas Hospital in São Paulo. She has served as Director of INI/Fiocruz, Head of the Treatment & Care Unit at Brazilian National AIDS Program and Director of the Rio de Janeiro AIDS Program. She has dedicated her career to HIV Care & Research and has published more than 100 papers in peer-reviewed journals.
    • Infectious Disease
    • Associate Vice Chancellor at University of North Carolina
    Myron S. Cohen is the Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology at University of North Carolina at Chapel Hill. He completed his medicine training at the University of Michigan and infectious disease training at Yale University. Dr. Cohen is the Director of the UNC Institute for Global Health and Infectious Disease, and the co-principal investigator of the NIH HIV Prevention Trials Network (HPTN). He is a member of the Institute of Medicine, the American Society of Clinical Investigation and the American Association of Physicians. Dr. Cohen’s awards include the Distinguished Career Award from the American Sexually Transmitted Diseases, the Smadel Award from the Infectious Disease Society, the O. Max Gardner Award from UNC, and the Award for Science from the State of North Carolina. Dr. Cohen lead the HPTN 052 trial which demonstrated that antiretroviral treatment of people with HIV infection prevents the sexual transmission, recognized by Science Magazine as the “Breakthrough of the Year” in 2011. Dr. Cohen is the author of more than 500 publications and two books. Dr. Cohen’s three decades of research has focused on prevention of the sexual transmission of HIV with extensive work in Malawi and the People’s Republic of China.
    • Not Boarded
    • Senior Fellow at University of Washington
    Andrew Mujugira is a physician-epidemiologist with more than a decade of experience in epidemiologic research, including HIV-1 prevention clinical trials of antiretroviral pre-exposure prophylaxis and acyclovir suppressive therapy in HIV-1 serodiscordant couples in seven African countries, and a randomized trial of pneumococcal polysaccharide vaccine in HIV-1 infected adults. He was part of the team that set up the Botswana National ARV program, the first universal access ART program in sub-Saharan Africa, and has served on STI guideline committees for the World Health Organization. He is currently a PhD candidate in Epidemiology at the University of Washington, and his dissertation research focuses on the opportunities and challenges of antiretroviral therapy for HIV-1 prevention in serodiscordant couples.
  • Robyn Eakle is a Senior Research at Wits Reproductive Health and HIV Institute in South Africa, and a Research Fellow pursuing a PhD at the London School of Hygiene and Tropical Medicine. Robyn has a Masters in Public Health from the University of Southern California, and a diverse background in business, philanthropy, and public health, having previously worked for corporations and law firms in the US as well as the Bill and Melinda Gates Foundation. She has been focused on the development and delivery of new HIV prevention technologies for the past seven years, in particular pre-exposure prophylaxis (PrEP) for HIV prevention. She is currently leading a demonstration project offering PrEP and Immediate Treatment to female sex workers in South Africa. Robyn’s research interests lie in the implementation of new prevention technologies, and the factors influencing successful implementation.
    • Internal Medicine
    • HIV
    Clinical Research Director at Bridge HIV, San Francisco Dept of Public Health
    Clinical Research Director at Bridge HIV, San Francisco Dept of Public Health
    • Assistant Clinical Professor of Medicine at UCSF
    Albert Liu, MD, MPH is the Clinical Research Director at Bridge HIV and an Assistant Clinical Professor of Medicine at UCSF. He is a board certified internist and instructs internal medicine residents in the care of underserved populations. After completing his MD at UCSF and MPH at UC Berkeley, he served as Medical Director of the Haight Ashbury Free Medical Clinic for 2 years. Dr. Liu’s research focuses on pre-exposure prophylaxis (PrEP), the use of HIV treatment medications to prevent new infections in HIV-negative individuals. He served as the Protocol Chair of the Demo Project, a PrEP Demonstration Project in San Francisco, Miami, and Washington DC. Dr. Liu was awarded an NIH grant to develop strategies to promote PrEP adherence in real-world settings. The EPIC study (Enhancing PrEP in Communities) will explore factors that influence adherence and risk behaviors in the Demo Project and develop and test a package of online and mobile health tools to promote the uptake and adherence to PrEP in diverse settings. Dr. Liu is also directing the San Francisco effort in an international study evaluating the safety of a rectal gel – known as a microbicide – to prevent the acquisition of HIV among men who have sex with men and transgender women. Dr. Liu serves as the co-chair of the PrEP Committee of San Francisco's Getting to Zero Consortium, a multisectorial effort to achieve Zero New Infections, Zero HIV deaths, and Zero HIV stigma in San Francisco.